Amphastar's board raised its buyback by $50 million on March 12, 2026, to offset dilution from equity compensation, while 2025 net income fell to $98.1 million and cash from operations dropped.
Latest Amphastar Pharmaceuticals news
We have not published a story on Amphastar Pharmaceuticals yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $223.6 million, plus short-term investments of $66.5 million, $290.1 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Amphastar Pharmaceuticals
Does Amphastar Pharmaceuticals have a share buyback?
Our latest story on this, dated Mar 16, 2026: "Amphastar adds $50 million to its share buyback program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals, Inc. trades under the ticker AMPH on NASDAQ.
Where is Amphastar Pharmaceuticals listed?
Amphastar Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:29A.
What is the SEC CIK of Amphastar Pharmaceuticals?
The SEC Central Index Key (CIK) for Amphastar Pharmaceuticals, Inc. is 1297184. Its filings are on SEC EDGAR.
How many shares does Amphastar Pharmaceuticals have outstanding?
42,537,944 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Amphastar Pharmaceuticals listed under?
Our directory records Amphastar Pharmaceuticals, Inc. under United States.
What does Amphastar Pharmaceuticals do?
Our directory classifies Amphastar Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Amphastar Pharmaceuticals?
The ISIN recorded for Amphastar Pharmaceuticals, Inc. is US03209R1032.
Does aibio.space cover Amphastar Pharmaceuticals?
aibio.space lists Amphastar Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What was Amphastar Pharmaceuticals's revenue last year?
$719.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Amphastar Pharmaceuticals profitable?
Amphastar Pharmaceuticals, Inc. reported net income of $98.1 million for the fiscal year ended Dec 31, 2025, and generated $156.1 million of cash from operations, per its annual report to the SEC.
How much does Amphastar Pharmaceuticals spend on research and development?
$85.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Amphastar Pharmaceuticals have?
$290.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Amphastar Pharmaceuticals (AMPH) stock news?
Our latest story on Amphastar Pharmaceuticals, dated Mar 16, 2026: "Amphastar adds $50 million to its share buyback program". Amphastar's board raised its buyback by $50 million on March 12, 2026, to offset dilution from equity compensation, while 2025 net income fell to $98.1 million and cash from operations dropped. Source.
What is Amphastar Pharmaceuticals's latest stock offering or financing news?
Our latest financing story, dated Mar 16, 2026: "Amphastar adds $50 million to its share buyback program". Amphastar's board raised its buyback by $50 million on March 12, 2026, to offset dilution from equity compensation, while 2025 net income fell to $98.1 million and cash from operations dropped. Source.
Investor discussion: Amphastar Pharmaceuticals
Members talk about Amphastar Pharmaceuticals (AMPH). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Amphastar Pharmaceuticals, newest first. Each line links the filing it comes from.
Financings
Announced a share repurchase program. SEC Form 8-K (Items 8.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:AMPH on TradingView.
SEC filings and registration
SEC name
Amphastar Pharmaceuticals, Inc.
CIK
1297184
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
AMPH (Nasdaq)
Fiscal year ends
December 31
Filer category
Large accelerated filer
Business address
11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730
Phone
909-980-9484
Shares outstanding
42,537,944 as of 2026-07-31 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Amphastar Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AMPH, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio